Associations of Fully Automated CSF and Novel Plasma Biomarkers With Alzheimer Disease Neuropathology at Autopsy

A multicentre validation study of the diagnostic value of plasma neurofilament light

(2021) Nicholas J. Ashton et al.   Nature Communications

Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia

(2020) Shorena Janelidze et al.   NATURE MEDICINE

Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration

(2020) Elisabeth H. Thijssen et al.   NATURE MEDICINE

Accuracy of Biomarker Testing for Neuropathologically Defined Alzheimer Disease in Older Adults With Dementia

(2020) Howard A. Fink et al.   ANNALS OF INTERNAL MEDICINE

Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts

(2020) Thomas K Karikari et al.   LANCET NEUROLOGY

Elecsys CSF biomarker immunoassays demonstrate concordance with amyloid-PET imaging

(2020) James D. Doecke et al.   Alzheimers Research & Therapy

Plasma p-tau181 accurately predicts Alzheimer’s disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline

(2020) Juan Lantero Rodriguez et al.   ACTA NEUROPATHOLOGICA

Diagnostic and prognostic value of serum NfL and p-Tau181 in frontotemporal lobar degeneration

(2020) Alberto Benussi et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer’s Disease Neuroimaging Initiative

(2020) Thomas K. Karikari et al.   MOLECULAR PSYCHIATRY

Amyloid‐ β PET and CSF in an autopsy‐confirmed cohort

(2020) Juhan Reimand et al.   Annals of Clinical and Translational Neurology

Time course of phosphorylated-tau181 in blood across the Alzheimer’s disease spectrum

(2020) Alexis Moscoso et al.   BRAIN

Increased plasma neurofilament light chain concentration correlates with severity of post-mortem neurofibrillary tangle pathology and neurodegeneration

(2019) Nicholas J. Ashton et al.   Acta Neuropathologica Communications

Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers

(2019) Gemma Salvadó et al.   Alzheimers Research & Therapy

Predicting clinical decline and conversion to Alzheimer’s disease or dementia using novel Elecsys Aβ(1–42), pTau and tTau CSF immunoassays

(2019) Kaj Blennow et al.   Scientific Reports

Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging

(2018) Suzanne E. Schindler et al.   Alzheimers & Dementia

CSF biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts

(2018) Oskar Hansson et al.   Alzheimers & Dementia

NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease

(2018) Clifford R. Jack et al.   Alzheimers & Dementia

Update on biomarkers for amyloid pathology in Alzheimer's disease

(2018) Nicholas J Ashton et al.   Biomarkers in Medicine

Biomarkers for Alzheimer's disease: current status and prospects for the future

(2018) K. Blennow et al.   JOURNAL OF INTERNAL MEDICINE

Multisite study of the relationships between antemortem [11C]PIB-PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology

(2018) Renaud La Joie et al.   Alzheimers & Dementia

Biomarkers for tau pathology

(2018) Michael Schöll et al.   MOLECULAR AND CELLULAR NEUROSCIENCE

Dichotomous scoring of TDP-43 proteinopathy from specific brain regions in 27 academic research centers: associations with Alzheimer’s disease and cerebrovascular disease pathologies

(2018) Yuriko Katsumata et al.   Acta Neuropathologica Communications

Clinical validity of cerebrospinal fluid Aβ42, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework

(2017) Niklas Mattsson et al.   NEUROBIOLOGY OF AGING

Concordance Between Different Amyloid Immunoassays and Visual Amyloid Positron Emission Tomographic Assessment

(2017) Shorena Janelidze et al.   JAMA Neurology

Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease

(2017) Niklas Mattsson et al.   JAMA Neurology

Plasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of CNS Injury in HIV Infection: A Cross-Sectional Study

(2016) Magnus Gisslén et al.   EBioMedicine

Brain collection, standardized neuropathologic assessment, and comorbidity in Alzheimer's Disease Neuroimaging Initiative 2 participants

(2015) Erin E. Franklin et al.   Alzheimers & Dementia

The Alzheimer’s Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans

(2015) Ju-Hee Kang et al.   Alzheimers & Dementia

CSF biomarker variability in the Alzheimer's Association quality control program

(2013) Niklas Mattsson et al.   Alzheimers & Dementia

CSF biomarkers cutoffs: the importance of coincident neuropathological diseases

(2012) Jon B. Toledo et al.   ACTA NEUROPATHOLOGICA

Comparison of Cerebrospinal Fluid Levels of Tau and Aβ 1-42 in Alzheimer Disease and Frontotemporal Degeneration Using 2 Analytical Platforms

(2012) David J. Irwin et al.   ARCHIVES OF NEUROLOGY

National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach

(2011) Thomas J. Montine et al.   ACTA NEUROPATHOLOGICA

Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects

(2009) Leslie M. Shaw et al.   ANNALS OF NEUROLOGY

Cerebrospinal Fluid β-Amyloid 42 and Tau Proteins as Biomarkers of Alzheimer-Type Pathologic Changes in the Brain

(2009) Tero Tapiola et al.   ARCHIVES OF NEUROLOGY